Call 650-263-7636 / Email

L-Arginine Improves Cognitive Impairment??

Front Cardiovasc Med 2022 Apr 12;9:868521.
L-Arginine Improves Cognitive Impairment in Hypertensive Frail Older Adults
Pasquale Mone 1 2 3, Antonella Pansini 2, Stanislovas S Jankauskas 1, Fahimeh Varzideh 1, Urna Kansakar 1, Angela Lombardi 1, Valentina Trimarco 4, Salvatore Frullone 2, Gaetano Santulli 1 4

Affiliations
1 Department of Medicine, Albert Einstein College of Medicine, New York, NY, United States.
2 Azienda Sanitaria Locale (ASL) Avellino, Avellino, Italy.
3 Campania University, Naples, Italy.
4 University of Naples “Federico II”, Naples, Italy.

Abstract
Cognitive impairment is a prevailing event in hypertensive patients and in frail older adults. Endothelial dysfunction has been shown to underlie both hypertension and cognitive dysfunction. Our hypothesis is that L-Arginine, which is known to ameliorate endothelial dysfunction, could counteract cognitive impairment in a high-risk population of hypertensive frail older adults. We designed a clinical trial to verify the effects of 4-weeks oral supplementation of L-Arginine on global cognitive function of hypertensive frail older patients. The study was successfully completed by 35 frail hypertensive elderly patients assigned to L-Arginine and 37 assigned to placebo. At follow-up, we found a significant difference in the Montreal Cognitive Assessment (MoCA) test score between the L-Arginine treated group and placebo (p: 0.0178). Moreover, we demonstrated that L-Arginine significantly attenuates Angiotensin II-induced mitochondrial oxidative stress in human endothelial cells.
In conclusion, our findings indicate for the first time that oral L-Arginine supplementation significantly improves cognitive impairment in frail hypertensive older adults.

Clinical trial registration: www.ClinicalTrials .gov, identifier: NCT04962841.

Keywords: L-Arg; L-Arginine; cardiac rehabilitation; cognitive impairment; endothelial (dys)function; frail adults; frailty.

Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

View Full-Text

Scientific Updates
Sponsored by Endothelix Inc.
View Archive

LATEST SCIENTIFIC UPDATES